Toxicology-on-a-Chip Model Introduction

Creative Biolabs provides you with our toxicology-on-a-chip model, which can accurately control the local environment and simulate human organ function in vitro and is an advantageous weapon to solve the key issues of new drug development.

Formation of Toxicology-on-a-chip Model

Our toxicology-on-a-chip model uses co-culture techniques that also have been widely to establish a microenvironment that is closer to the body and maintains cell functions. By establishing a nylon scaffold that allows a three-dimensional culture of non-parenchymal cells including Kupffer cells, stellate cells, sinusoidal endothelial cells, and bile duct endothelial cells, which can maintain the specific functions of the long-term, form bile duct-like structures, and respond to inflammatory stimuli as well as simulating the toxic response of a whole organ to drug candidates.

A liver chip system for drug toxicity testing.Fig 1. A liver chip system for drug toxicity testing. (Cong, 2020)

Biomarkers for Drug Toxicity Evaluation Utilized with Organ Chips

Selecting biomarkers for effective drug toxicity testing is a critical step. Creative Biolabs provides you with an overview of the toxic biomarkers utilized in our toxicology-on-a-chip models.

Toxicity Biomarker Specification
Hepatotoxicity ALT (alanine aminotransferase)
AST (aspartate aminotransferase)
Diagnostic marker of liver damage
ALP (alkaline phosphatase) Diagnostic marker of cholestatic injury
K18 (keratin-18) Early detection biomarker
GST-α (glutathione S-transferase α) Early detection biomarker
CYP (cytochrome P450) Metabolic ability biomarker
miRNA-122, miRNA-192 Genomic markers
CDH-5 (cadherin-5) Proteomics biomarker
Nephrotoxicity GFR (glomerular filtration rate) Diagnostic marker of renal function
SCr levels and urine output Diagnostic marker of AKI (acute kidney injury)
KIM-1 (kidney injury molecule-1) Early detection biomarker
NAG (N-acetyl-β-glucosaminidase) Early detection biomarker
NGAL (neutrophil gelatinase-associated lipocalin) Early detection biomarker
CYs C (cystatin C) Early detection biomarker
TEER (transendothelial resistance) Biomarker of barrier functions
miRNAs Genomic markers
Cardiotoxicity LVDP (left ventricular formation pressure)
LVSP (left ventricular systolic pressure)
Diagnostic marker of myocardial injury
miR-146a, miR-1, miR-133, miR-208, miR-499 Genomic markers
beating frequency, systolic stress, field potential Mechanical markers
TEER Biomarker of barrier functions
Neurotoxicity miR-425-p, miR-21, miR-93, miR-191, miR-499, miR-328, miR-362-3p, miR-451, miR-486a Genomic markers
SP, sCD40L, TIMP-1, MDA, CK-18 Early detection biomarkers
Other toxicities CD64, C-reactive protein Biomarker of small/large intestine
NOS isoenzymes Breath biomarkers
HO (heme oxygenase) Biomarker of upper respiratory tract viral infections
CYP (cytochrome P450)
H2O2
Biomarker of pulmonary diseases
TEER Biomarker of barrier functions

Table 1. Some common biomarkers for drug toxicity evaluation. (Cong, 2020)

Advanced Toxicology-on-a-chip Model at Creative Biolabs

Toxicology-on-a-chip Model Introduction

Applications of Toxicology-on-a-chip Model

  • Improve the accuracy of drug preclinical test results for toxicity screening by using our reconstructed in vitro models.
  • Simulate the toxic effects of drug candidates on different cells, tissues, or organs of the human body.
  • Simulate the toxic response of whole organs to drug candidates.

Why Choose Us

Drug toxicity is one of the major reasons for post-market drug withdrawal; therefore, it is crucial to perform preclinical toxicity testing on candidate drugs. Toxicology-on-a-chip model of Creative Biolabs with the technology to achieve rapid high-throughput production of organ chip tissue will greatly reduce your production costs and operational difficulties.

In addition to the toxicology-on-a-chip model, we offer a diverse range of alternative models that might be of interest to you:

Related Services

With years of experience in drug discovery, a group of specialists at Creative Biolabs possesses a keen insight into diverse research demands from our worldwide clients. Beyond delivering premium disease-on-a-chip models, we are dedicated to propelling your research pursuits by presenting a diverse and comprehensive range of 3D biology-based services. We warmly invite you to connect with us to expedite the achievements of your project.

Reference

  1. Cong, Y.; et al. Drug toxicity evaluation based on organ-on-a-chip technology: A review. Micromachines. 2020, 11: 381.
Research Model

Related Sections:

USA
UK
Germany
Inquiry Basket
Copyright © Creative Biolabs. All Rights Reserved.
Top